<i>KRAS</i> G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients

Abstract

This study aims to investigate the molecular characteristics of Chinese gastric cancer patients. In our study, the <i>KRAS</i>, <i>BRAF</i>, and <i>PIK3CA</i> mutation status of 485 GC patients were analyzed by Sanger sequencing. Kaplan-Meier analysis was used to plot survival curves according to different genotypes. The results show that the frequency of <i>KRAS</i>, <i>BRAF</i> and <i>PIK3CA</i> mutations were 4.1%, 1.2% and 3.5%, respectively. <i>BRAF</i> mutations were significantly concentrated in stage III and IV gastric cancer (<i>P</i>=0.009). <i>KRAS</i> G12V mutation carriers have much shorter OS than other mutation carriers and wild-type group patients (<i>P</i>=0.013). In conclusion, only the <i>KRAS</i> G12V mutation has an adverse effect on patient survival.